Skip to main content
Clinical Trials/NCT01055093
NCT01055093
Recruiting
Not Applicable

Prospective Study on Diabetes Mellitus and Its Complications in Newly Diagnosed Adult Patients

German Diabetes Center1 site in 1 country2,000 target enrollmentSeptember 1, 2005

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus, Type 1
Sponsor
German Diabetes Center
Enrollment
2000
Locations
1
Primary Endpoint
Change of insulin sensitivity (M-Value)
Status
Recruiting
Last Updated
9 months ago

Overview

Brief Summary

The aim of the prospective observational GDC-Study in patients with newly diagnosed diabetes mellitus aged 18-69 years at inclusion into the study is to characterize in detail the clinical, metabolical and immunological phenotype and monitor the progression of the disease and to compare the phenotype to glucose tolerant humans of similar age, body mass and sex distribution.

Detailed Description

In detail, the following questions will be answered: 1. Are there different phenotypes with respect to insulin secretion, insulin sensitivity, micro- and macrovascular status and diabetic neuropathy at time of diagnosis? 2. Which factors modify the progression of the disease (Nutrition, subclinical inflammation, energy metabolism and physical activity)? 3. Can we identify subgroups at baseline with different progression of the disease? Patients are thoroughly examined at baseline and after 2, 5, and 10 years with annual telephone contacts in between.

Registry
clinicaltrials.gov
Start Date
September 1, 2005
End Date
September 1, 2040
Last Updated
9 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
German Diabetes Center
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of diabetes mellitus according to ADA criteria
  • Age 18-69
  • Diabetes duration since diagnosis \< 12 months
  • Control cohort: proven normal glucose tolerance according to ADA criteria

Exclusion Criteria

  • Diabetes mellitus category 3 B-H (ADA criteria)
  • Pregnancy
  • Severe renal, liver or heart disease
  • malignant cancer
  • severe psychiatric illness or addiction
  • participation in an intervention trial

Outcomes

Primary Outcomes

Change of insulin sensitivity (M-Value)

Time Frame: 2 and 5 years

measurement of whole body insulin sensitivity with hyperinsulinamic euglicamic clamp

Secondary Outcomes

  • Incidence of any diabetic complication(2-10 years)
  • Change of insulin secretion(2 and 5 years)

Study Sites (1)

Loading locations...

Similar Trials